Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.70 |
| ▸ | NQO2 | P16083 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3091715 | 0.92 | MET (0.58) | METNQO2 | |
| SCHEMBL3090584 | 0.89 | MET (0.73) | METNQO2 | |
| SCHEMBL3090924 | 0.86 | MET (0.67) | METNQO2 | |
| SCHEMBL3081927 | 0.86 | MET (0.56) | METNQO2 | |
| SCHEMBL31690164 | 0.86 | MET (0.67) | METNQO2 | |
| SCHEMBL3092228 | 0.85 | MET (0.68) | METNQO2 | |
| SCHEMBL3087125 | 0.85 | MET (0.59) | METNQO2 | |
| Hydrochloric Acid SCHEMBL31690372 | 0.85 | MET (0.66) | METNQO2 | |
| SCHEMBL3092259 | 0.84 | MET (0.52) | METNQO2 | |
| SCHEMBL15104625 | 0.84 | MET (0.53) | METNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2754660-B1 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2016-11-02 | — | — | EP | claimed |
| US-9284300-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2016-03-15 | — | — | US | claimed |
| US-20150011534-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-01-08 | — | — | US | claimed |
| US-8927540-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2015-01-06 | — | — | US | claimed |
| EP-2164843-B1 | PYRIDAZINONE DERIVATES | MERCK PATENT GMBH (DE) | 2014-10-29 | — | — | EP | claimed |
| US-8580781-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2013-11-12 | — | — | US | claimed |
| US-20130184261-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-07-18 | — | — | US | claimed |
| US-20100234354-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | claimed |
| EP-2754660-B1 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2016-11-02 | — | — | EP | disclosed |
| US-9284300-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2016-03-15 | — | — | US | disclosed |
| US-20150011534-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-01-08 | — | — | US | disclosed |
| US-8927540-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-8921357-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2014-12-30 | — | — | US | disclosed |
| CN-101743241-B | Pyridazinone derivates | MERCK PATENT GMBH | 2013-12-25 | — | — | CN | disclosed |
| US-8580781-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-20130184260-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| US-20130184261-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| US-20100234354-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | disclosed |
| EP-2164843-A1 | PYRIDAZINONE DERIVATES | Merck Patent GmbH (DE) | 2010-03-24 | — | — | EP | disclosed |
| WO-2009006959-A1 | PYRIDAZINONE DERIVATES | MERCK PATENT GMBH (DE) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184261-A1 | PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | MET 1/4885NQO2 562/4885 |
| US-20130184260-A1 | PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | MET 1/4885NQO2 558/4885 |
| US-20150011534-A1 | PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | MET 1/4885NQO2 558/4885 |
| US-20100234354-A1 | PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | MET 1/4885NQO2 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.